Gossamer Bio secures option to acquire Respira Therapeutics
Source: SeekingAlpha
2025-09-25 08:00:57 ET
More on Gossamer Bio
- Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout
- Gossamer Bio: A Critical Year Ahead
- Gossamer Bio higher as UBS upgrades on upcoming data catalyst
- Seeking Alpha’s Quant Rating on Gossamer Bio
- Historical earnings data for Gossamer Bio
Read the full article on Seeking Alpha
For further details see:
Gossamer Bio secures option to acquire Respira Therapeutics
Gossamer Bio Inc.
NASDAQ: GOSS
GOSS Trading
-5.9% G/L:
$0.437 Last:
3,492,336 Volume:
$0.4575 Open:
GOSS Latest News
March 17, 2026 04:01:00 pm
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
March 01, 2026 04:07:00 pm
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
GOSS Stock Data
$545,079,462
180,998,785
0.97%
49
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
